Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	13.98B +50.0%
Revenue (ttm)	16.30B +2.2%
Net Income	633.23M +41.0%
EPS	0.25 +37.8%
Shares Out	2.52B
PE Ratio	22.46
Forward PE	23.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,274,153
Open	5.60
Previous Close	5.80
Day's Range	5.47 - 5.74
52-Week Range	2.84 - 9.86
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, and antibiotics. It also provides calcium iron zinc oral solut...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,039
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2025, SHA:600664's revenue was 15.96 billion, a decrease of -1.31% compared to the previous year's 16.18 billion. Earnings were 361.60 million, a decrease of -42.50%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error